Evaluating OBI-833/OBI-821 for Esophageal Cancer Recurrence

A Randomized, Open-Label, Phase 2 Study to Evaluate Adjuvant OBI-833/OBI-821 Therapy in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer at High Risk for Recurrence

This study is testing if a new treatment called OBI-833/OBI-821 can help prevent esophageal cancer from coming back in patients who are at high risk after surgery.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 20 Years and up
• Sex: All
• Sponsor: National Taiwan University Hospital (Academic / other)
• Drugs / interventions: rituximab, alemtuzumab, natalizumab, Immunotherapy, cyclophosphamide
• Locations: 1 site (Taipei)
• Trial ID: NCT05376423 on ClinicalTrials.gov

What this trial studies

This Phase 2 study aims to evaluate the effectiveness of OBI-833/OBI-821 as an adjuvant therapy in patients with locally advanced, Globo H-positive esophageal cancer who are at high risk for recurrence. Participants will have undergone preoperative cisplatin-based chemoradiotherapy followed by esophagectomy. The study will assess the impact of the treatment on recurrence rates in this specific patient population. The eligibility criteria include specific pathologic staging and Globo H expression levels.

Who should consider this trial

Good fit: Ideal candidates are adults aged 20 and older with locally advanced, Globo H-positive esophageal cancer who have undergone specific preoperative treatments.

Not a fit: Patients with esophageal cancer that does not express Globo H or those who do not meet the staging criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the risk of cancer recurrence in patients with advanced esophageal cancer.

How similar studies have performed: While there have been studies on adjuvant therapies for esophageal cancer, the specific use of OBI-833/OBI-821 in this context is novel.

Eligibility criteria

Inclusion Criteria:

1. Male or female patients, 20 years of age or older at the time of consent.
2. Pathologically or cytologically confirmed diagnosis of esophageal cancer (including squamous cell carcinoma and adenocarcinoma) whose postneoadjuvant pathologic stage is ypT1-4 AND ypN1-3 according to the AJCC Cancer Staging System, 8th Edition.
3. Patients have been treated with preoperative cisplatin-based chemoradiotherapy followed by esophagectomy with lymph node dissection for locally advanced esophageal cancer (defined by the above criterion).
4. Postneoadjuvant pathologic staging: ypT1-4 and ypN1-3.
5. Globo H IHC H-score ≥1 in the surgical tumor specimen from the primary site/or lymph node (if the primary site is not available). The Globo H expression will be determined by a qualified laboratory.
6. R0 (no residual tumor on the surgical margin of the resected tumor specimen).
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
8. Organ Function Requirements - Subjects must have adequate organ functions as defined below:

   * AST/ALT ≤ 3X ULN (upper limit of normal)
   * Total bilirubin ≤ 2X ULN
   * Serum creatinine ≤ 1.5X ULN
   * ANC ≧ 1,500 /μL
   * Platelets ≧ 100,000/μL
9. All eligible patients of childbearing potential must use effective contraception during study treatment and for at least 2 months after the last dose of OBI-833/OBI-821. Subjects not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in the study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.
10. Ability to understand and the willingness to sign a written informed consent document according to institutional guidelines.

Exclusion Criteria:

1. Subjects who cannot be randomized within 8 weeks after the esophageal cancer surgery.
2. Subjects who are pregnant or breast-feeding at entry.
3. Subjects with splenectomy.
4. Has prior malignancy, except (a) adequately treated basal cell or squamous cell skin cancer; (b) in situ cervical cancer; (c) previously diagnosed malignancy which has been adequately treated and shown no evidence of recurrence for more than 5 years.
5. Subjects with HIV infection, active hepatitis B infection, or active hepatitis C infection.
6. Subjects with any autoimmune or other disorders requiring IV/oral steroids or immunosuppressive or immunomodulatory therapies.

   - e.g., type 1 juvenile-onset diabetes mellitus, antibody positive for rheumatoid arthritis, Graves disease, Hashimoto thyroiditis, lupus, scleroderma, systemic vasculitis, hemolytic anemia, immune mediated thrombocytopenia, Crohn disease, ulcerative colitis, and psoriasis.
7. Subjects with any known uncontrolled comorbid illness, including ongoing or active infections, symptomatic congestive heart failure (NYHA\>2), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
8. Subjects who have received any of the following medications within 4 weeks prior to randomization:

   * Immunotherapy, including monoclonal antibodies, cytokines, interferons, and checkpoint inhibitors.
   * Immunosuppressants, including cyclosporin, rapamycin, tacrolimus, rituximab, alemtuzumab, natalizumab, and cyclophosphamide.
   * Other biologics, including G-CSF and other hematopoietic growth factors.
   * Live attenuated vaccines.
   * IV/oral steroids except single prophylactic use in CT/MRI scan or other one-time use in approved indications. Use of inhaled and topical (except on the injection site) steroids is allowed.
   * Alternative and complementary medicine that may affect the immune system.
   * Other investigational drugs
9. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0), except for alopecia and laboratory values listed in the inclusion criteria.
10. Subjects with any known severe allergies (e.g., anaphylaxis) to any active or inactive ingredients in the study drugs.
11. Any other reason that the investigator deems the patient as unsuitable for the study.

Where this trial is running

Taipei

• National Taiwan University Hospital — Taipei, Taiwan (Recruiting)

Study contacts

• Principal investigator: Jang-Ming Lee — Department of Surgery, National Taiwan University Hospital. Taipei, Taiwan
• Study coordinator: Jang-Ming Lee

Conditions Esophageal Cancer